Molecular aspects of chronic radiation enteritis

Clinical and Investigative Medicine

Volumn 34, Issue 3, 2011, Pages

  Zhu, Yanfei ^a   Zhou, Jing ^a   Tao, Guoqing ^a  

^a WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RHO KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; CHRONIC DISEASE; ENTERITIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CHRONIC DISEASE; ENTERITIS; HUMANS; RADIATION INJURIES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80051761933     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Theis VS, Sripadam R, Ramani V, et al. Chronic radiation enteritis. Clin Oncol (R Coll Radiol) 2010;22:70-83.
2. O'Sullivan B, Levin W. Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin Radiat Oncol 2003;13:274-89.
3. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 2007;8:1007-17.
4. Ruiz Tovar J, Morales V, Hervas A, et al. Late gastrointestinal complications after pelvic radiotherapy: radiation enteritis. Clin Transl Oncol 2009;11:539-43.
5. Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut 2005;54:1051-4.
6. Onodera H, Nagayama S, Mori A, et al. Reappraisal of surgical treatment for radiation enteritis. World J Surg 2005;29:459-63.
7. Andreyev HJ. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol) 2007;19:790-9.
8. Gillespie C, Goode C, Hackett C, et al. The clinical needs of patients with chronic gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther 2007;26:555-63.
9. Nguyen NP, Antoine JE, Dutta S. Karlsson U, Sallah S. Current concepts in radiation enteritis and implications for future clinical trials. Cancer 2002;95:1151-63.
10. Tyurina YY, Tyurin VA, Epperly MW, et al. Oxidative lipidomics of gamma-irradiation-induced intestinal injury. Free Radic Biol Med 2008;44:299-314.
11. Konishi T, Watanabe T, Nagawa H, et al. Treatment of local ischaemia: another promising approach for gastrointestinal complications of pelvic radiotherapy. Gut 2006;55:109.
12. Yarnold J, Brotons MC. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol 2010;97:149-61.
13. Gervaz P, Morel P, Vozenin-Brotons MC. Molecular aspects of intestinal radiation-induced fibrosis. Curr Mol Med 2009;9:273-80.
14. Haydont V, Vozenin-Brotons MC. Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features. World J Gastroenterol 2007;13:2675-83.
15. Pohlers D, Brenmoehl J, Loffler I, et al. TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta 2009;1792:746-56.
16. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002;14:681-5.
17. Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006;17:19-27.
18. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, TGF-beta Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35:661-4.
19. Lee JW, Tutela JP, Zoumalan RA, et al. Inhibition of Smad3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy. Arch Otolaryngol Head Neck Surg 2010;136:714-9.
20. Lee JW, Zoumalan RA, Valenzuela CD, et al. Regulators and mediators of radiation-induced fibrosis: Gene expression profiles and a rationale for Smad3 inhibition. Otolaryngol Head Neck Surg 2010;143:525-30.
21. Haydont V, Mathe D, Bourgier C, et al. Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. Radiother Oncol 2005;76:219-25.
22. Mihaescu A, Santen S, Jeppsson B, Thorlacius H. Rho kinase signalling mediates radiation-induced inflammation and intestinal barrier dysfunction. Br J Surg 2011;98:124-31.
23. Haydont V, Bourgier C, Vozenin-Brotons MC. Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity. Br J Radiol 2007;80:S32-40.
24. Vardouli L, Vasilaki E, Papadimitriou E, et al. A novel mechanism of TGFbeta-induced actin reorganization mediated by Smad proteins and Rho GTPases. FEBS J 2008;275:4074-87.
25. Abayomi J, Kirwan J, Hackett A. The prevalence of chronic radiation enteritis following radiotherapy for cervical or endometrial cancer and its impact on quality of life. Eur J Oncol Nurs 2009;13:262-7.
26. Larsen A, Reitan JB, Aase ST, Hauer-Jensen M. Long-term prognosis in patients with severe late radiation enteropathy: a prospective cohort study. World J Gastroenterol 2007;13:3610-3.
27. Moriyama T, Nagatoya K. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. Drug News Perspect 2004;17:29-34.
28. Haydont V, Bourgier C, Pocard M, et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007;13:5331-40.
29. Haydont V, Gilliot O, Rivera S, et al. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int J Radiat Oncol Biol Phys(2007;68:1471-82.
30. Yamashita M, Otsuka F, Mukai T, et al. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol 2008;196:601-13.
31. Wang J, Boerma M, Fu Q, Kulkarni A, Fink LM, Hauer-Jensen M. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys 2007;68:1483-90.
32. Keskek M, Gocmen E, Kilic M, et al. Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats. J Surg Res 2006;135:76-84.
33. Okoshi K, Kubo H, Nagayama S, et al. All-trans-retinoic acid attenuates radiation-induced intestinal fibrosis in mice. J Surg Res 2008;150:53-9.
34. Milliat F, Sabourin JC, Tarlet G, et al. Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy. Am J Pathol 2008;172:691-701.
35. Berbee M, Fu Q, Boerma M, Wang J, Kumar KS, Hauer-Jensen M. gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress afer total-body irradiation by an HMG-CoA reductase-dependent mechanism. Radiat Res 2009;171:596-605.
36. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of radiation-induced changes in human gene expression. Nature 2009;459:587-91.
37. Smirnov DA, Morley M, Shin E, et al. Genetic analysis of radiation-induced changes in human gene expression. Nature(2009;459:587-91.
38. Kruse JJ, Stewart FA. Gene expression arrays as a tool to unravel mechanisms of normal tissue radiation injury and prediction of response. World J Gastroenterol 2007;13:2669-74.
39. Correa CR, Cheung VG. Genetic variation in radiation-induced expression phenotypes. Am J Hum Genet 2004;75:885-90.
40. Marshall GT, Thirlby RC, Bredfeldt JE, Hampson NB. Treatment of gastrointestinal radiation injury with hyperbaric oxygen. Undersea Hyperb Med 2007;34:35-42.
41. Safra T, Gutman G, Fishlev G, et al. Improved quality of life with hyperbaric oxygen therapy in patients with persistent pelvic radiation-induced toxicity. Clin Oncol (R Coll Radiol) 2008;20:284-7.